ArabFinance: The Egyptian International Pharmaceutical Industries Company (EIPICO) (PHAR) has intended to establish a new project to a produce vital drugs with total cost EGP 1.2 billion, according to the company’s October 18thstatement filed to the Egyptian Exchange.
EIPICO has not determined the financing method of the project, however, it received many bank proposals for financing which are under examination.
The company posted a consolidated net profit of EGP 262.201 million in the first half (H1) of 2020, a 34% decrease from EGP 398.350 million achieved in H1 2019.
EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international pharmaceutical companies to produce their products locally and replace the imported ones.
Copyright © 2020 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
